8种抗真菌药物对浅表真菌病致病菌株体外敏感性检测

中国真菌学杂志　 2017, Vol. 12 　Issue (5): 279-282,278.

8种抗真菌药物对浅表真菌病致病菌株体外敏感性检测

吴伟伟^1,2, 王千¹, 龚杰¹, 万喆¹, 王爱平¹, 李若瑜¹

1. 北京大学第一医院皮肤性病科北京大学真菌和真菌病研究中心, 北京 100034;
2. 海南省皮肤病医院, 海口 570206

收稿日期:2017-03-04 出版日期:2017-10-28 发布日期:2017-10-28
通讯作者: 李若瑜,E-mail:mycolab@126.com E-mail:mycolab@126.com
作者简介:吴伟伟,男(汉族),博士,副主任医师.E-mail:vigorwu@bjmu.edu.cn

In vitro susceptibility testing of eight antifungal agents against pathogenic fungi isolated from superficial mycoses

WU Wei-wei^1,2, WANG Qian¹, GONG Jie¹, WAN Zhe¹, WANG Ai-ping¹, LI Ruo-yu¹

1. Department of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing 100034, China;
2. Department of Dermatology and Venereology, Hainan Provinical Hospital of Skin Disease, Haikou 570206, China

Received:2017-03-04 Online:2017-10-28 Published:2017-10-28

摘要/Abstract

摘要：

目的确定8种抗真菌药物对100株浅表致病真菌的体外药物敏感性。方法参考美国临床和实验室标准化研究所（Clinical and Laboratory Standards Institute，CLSI）微量液基稀释法M27-A3和M38-A2方案，采用8种抗真菌药物对100株常见浅表致病真菌进行体外药物敏感性测定。结果体外药敏实验结果显示，8种药物对皮肤癣菌表现出良好的体外药物敏感性，其中特比萘芬（GM MIC，0.011 μg/mL，MIC范围，0.004~0.06 μg/mL）具有最强的抗真菌活性。咪康唑（GM MIC，0.147 μg/mL，MIC范围0.015~1 μg/mL）具有最强的抗念珠菌活性。酮康唑（GM MIC，0.097 μg/mL，MIC范围0.03~1 μg/mL）则对马拉色菌具有最佳体外抗真菌效果。结论体外药敏实验结果表明常见浅表致病真菌对8种常用抗真菌药物表现出不同的敏感性。酮康唑具有广谱高效的特点，对临床常见皮肤癣菌、念珠菌、马拉色菌均具有良好的体外抗真菌活性。特比萘芬和萘替芬对皮肤癣菌具有最佳的抗真菌活性。

关键词: 抗真菌剂, 药敏实验, 微量液基稀释法, 浅表真菌病

Abstract:

Objective To investigate the in vitro activity of 8 antifungal agents against 100 strains of pathogenic fungi isolated from patitens with superficial mycoses.Methods The antifungal susceptibility testing was investigated following Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution methods.Eight antifungal agents were evaluated against 45 dermatophyte strains,35 Candida strains and 15 Malassezia strains.Results Our minimum inhibitory concentration (MIC) results revealed that terbinafine (GM MIC,0.011 μg/mL;MIC range,0.004-0.06 μg/mL) had the strongest antifungal activity against Dermatophyte,miconazole (GM MIC,0.147 μg/mL;MIC range,0.015-1 μg/mL) against Candida,and ketoconazole (GM MIC,0.097 μg/mL;MIC range,0.03-1 μg/mL) against Malassezia.Conclusions The in vitro susceptibility testing indicates that common superficial pathogenic fungi exhibit variable susceptibilities to 8 antifungal agents.Ketoconazole has a potent antifungal activity for dermatophyte,Candida and Malassezia.Terbinafine and naftifine were the most active agents for Dermatophyte.

Key words: antifungal agents, susceptibility testing, broth microdilution, superficial mycoses

中图分类号:

R978.5

吴伟伟, 王千, 龚杰, 万喆, 王爱平, 李若瑜. 8种抗真菌药物对浅表真菌病致病菌株体外敏感性检测[J]. 中国真菌学杂志, 2017, 12(5): 279-282,278.

WU Wei-wei, WANG Qian, GONG Jie, WAN Zhe, WANG Ai-ping, LI Ruo-yu. In vitro susceptibility testing of eight antifungal agents against pathogenic fungi isolated from superficial mycoses[J]. Chinese Journal of Mycology, 2017, 12(5): 279-282,278.

参考文献

[1] Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of filamentous fungi;Approved standard-2nd Ed.CLSI document M38-A2[S].Wayne PA:.Clinical Laboratory Standards Institute.2008.
[2] Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts;Approved standard-3rd Ed.CLSI document M27-A3[S].Wayne PA:Clinical and Laboratory Standards Institute,2008.
[3] Leeming JP,Notman FH.Improved methods for isolation and enumeration of Malassezia furfur from human skin[J].J Clin Microbiol,1987,25(10):2017-2019.
[4] Miranda KC,de Araujo CR,Costa CR,et al.Antifungal activities of azole agents against the Malassezia species[J].Int J Antimicrob Agents,2007,29(3):281-284.
[5] Badali H,Mohammadi R,Mashedi O,et al.In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs[J].Mycoses,2015,58(5):303-307.
[6] Fernández-Torres B,Carrillo AJ,Martín E,et al.In vitro activities of 10 antifungal drugs against 508 dermatophyte strains[J].Antimicrob Agents Chemother,2001,45(9):2524-2528.
[7] Adimi P,Hashemi SJ,Mahmoudi M,et al.In vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran[J].Iran J Pharm Res,2013,12(3):537-545.
[8] Jo Siu WJ,Tatsumi Y,Senda H,et al.Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis[J].Antimicrob Agents Chemother,2013,57(4):1610-1616.
[9] Gupta AK,Kohli Y,Li A,et al.In vitro susceptibility of the seven Malassezia species to ketoconazole,voriconazole,itraconazole and Terbinafine[J].Br J Dermatol,2000,142(4):758-765.
[10] Nakamura Y,Kano R,Murai T,et al.Susceptibility testing of Malassezia species using the urea broth microdilution method[J].Antimicrob Agents Chemother,2000,44(8):2185-2186.
[11] Garau M,Pereiro M Jr,del Palacio A.In vitro susceptibilities of Malassezia species to a new triazole,albaconazole (UR-9825),and other antifungal compounds[J].Antimicrob Agents Chemother,2003,47(7):2342-2344.
[12] Rojas FD,Sosa Mde L,Fernández MS,et al.Antifungal susceptibility of Malassezia furfur,Malassezia sympodialis,and Malassezia globosa to azole drugs and amphotericin B evaluated using a broth microdilution method[J].Med Mycol,2014,52(6):641-646.
[13] Carrillo-Muñoz AJ,Rojas F,Tur-Tur C,et al.In vitro antifungal activity of topical and systemic antifungal drugs against Malassezia species[J].Mycoses,2013,56(6):571-575.